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INTRODUCTION
Diabetic nephropathy is the most common cause of end
stage renal disease in developed countries and a major cause
of morbidity and mortality in patients with diabetes. It is
characterized by structural abnormalities including hyper-
trophy of both glomerular and tubular elements, increase in
the thickness of glomerular basement membranes, and pro-
gressive accumulation of extracellular matrix components.
It also results in functional alterations including the early
increase in the glomerular filtration rate with intraglomeru-
lar hypertension, subsequent proteinuria, systemic hyper-
tension, and eventual loss of renal function (1-4). The devel-
opment of irreversible renal change in diabetes mellitus such
as glomerulosclerosis and tubulointerstitial fibrosis results
ultimately in renal failure. 
It has been established that transforming growth factor
(TGF)- 1 is a critical cytokine involved in diabetes-induced
extracellular matrix accumulation in both cell culture and
animal models of diabetic kidney disease. Investigations of
glomerular mesangial cells and proximal tubular cells have
demonstrated that high glucose media induce the enhanced
expression of TGF- 1 mRNA and protein and the biosyn-
thesis of collagen and other extracellular matrix constituents
(5-9). Several in vivo studies have also reported that TGF- 1
expression is elevated in diabetic kidneys (10-14). TGF- is a
multifunctional cytokine that plays an important role in heal-
ing wounds and repairing tissues. In mammals the cytokine
has three isoforms i.e., TGF- 1, 2, and 3, whose biological
properties are nearly identical. Among the three isoforms,
TGF- 1 is known to contribute mostly to the pathogenesis
of tissue fibrosis of organs such as kidney, liver, lungs, and
heart and scarring of superficial tissues. TGF- 1 plays a cen-
tral role in tissue repair by stimulating the balanced expres-
sion of extracellular matrix such as collagen, fibronectin, and
matrix proteoglycans. However, persistent injury with sus-
tained autoinduction of TGF- 1 overrides normal termina-
tion signals and leads to the continuous production of TGF- 1
and extracellular matrix; thus resulting in tissue fibrosis (15,
16). Therefore, anti-TGF- 1 or anti-fibrotic therapies have
been attempted by administering various reagents: anti-TGF-
1 antibody, interferon- , anti-oxidants such as  -tocopherol,
and decorin (17-20).
In diabetic kidney models, anti-TGF- 1 antibodies sig-
nificantly suppressed renal hypertrophy and expression of
genes encoding extracellular matrix components (19). Ther-
apy with antisense TGF- 1 oligodeoxynucleotides (ODNs)
decreased TGF- 1 production and reduced hyperglycemia-
induced proximal tubular cell hypertrophy in vitro and par-
tially prevented the increase in kidney weight and extracel-
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Effect of Antisense TGF- 1 Oligodeoxynucleotides in Streptozotocin-
Induced Diabetic Rat Kidney
Transforming growth factor (TGF)- 1 is an important fibrogenic factor that is in-
volved in the pathogenesis of diabetic nephropathy. We evaluated the effect of cir-
cular antisense TGF- 1 oligodeoxynucleotides (ODNs) on the TGF- 1 expression
in the rat mesangial cell culture and in streptozotocin (STZ)-induced diabetic rats.
Circular antisense TGF- 1 ODNs were found to be stable in rat serum, significantly
decreasing TGF- 1 mRNA expression compared with linear antisense ODNs in
the rat mesangial cell culture. Circular antisense TGF- 1 ODNs were introduced
into the tail vein of normal rats using hemagglutinating virus of Japan (HVJ)-liposome-
mediated gene transfer method and were confirmed to be delivered effectively into
the kidney, liver, lungs, and spleen. To inhibit the overexpression of TGF- 1 in dia-
betic kidneys, we introduced circular antisense TGF- 1 ODNs into the STZ-induced
diabetic rats. On day 13 after circular antisense TGF- 1 ODNs injection, TGF- 1
mRNA and protein expression markedly decreased and urinary TGF- 1 excretion
rate also dropped in the circular antisense TGF- 1 ODNs-treated diabetic rats.
These results suggest that circular antisense TGF- 1 ODNs may be a useful tool
for developing new therapeutic application for progressive diabetic nephropathy.
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lular matrix expression (21). Anti-TGF- 1 therapies on dia-
betic models to date suggested that blockade of the biologi-
cal actions of TGF- 1 may be useful in preventing matrix
accumulation at the early stage of diabetic nephropathy.
In recent years, gene therapy has been tried actively with
antisense ODNs to block the aberrant gene expression impli-
cated in many diseases. Antisense ODNs can work through
several potential mechanisms involving hybridization with
mRNA and function of RNase H that has the ability to de-
grade the target message (22). However, biological instabil-
ity is the first problem to consider when delivering ODNs
to cells. Unmodified phosphodiester backbone ODNs are
rapidly degraded in the biological fluid by a combination of
both endo- and exonucleases. To overcome this problem, a
variety of chemically modified ODNs have been developed:
phosphorothioates, methylphosphonates, and phosphorami-
date analogues (22-25). Nonetheless, most of the modified
ODNs exhibited problems as well. Phosphorothioate ODNs
have non-sequence related toxicity, while methylphosphonate
ODNs show resistance to RNase H (22, 26). Compared with
natural DNA/RNA complexes, phosphoramidate oligonu-
cleotides are weak activators of RNase H (22). Given these
problems, circular antisense ODNs only structurally modi-
fied for stability against nucleases have been developed recent-
ly (27). These were in contrast with those of other chemical-
ly modified ODNs, designed only through structural modi-
fication.
The aim of the present study was to investigate the effect
of circular antisense TGF- 1 ODNs on the TGF- 1 expres-
sion in the rat mesangial cell culture and in streptozotocin
(STZ)-induced diabetic rats. 
MATERIALS AND METHODS
Synthesis of circular antisense TGF- 1 ODNs
Circular antisense TGF- 1 ODNs were synthesized as des-
cribed previously (27, 28). The selection of antisense ODNs
for TGF- 1 was performed using the DNAsis program (Hi-
tach Software, San Bruno, CA, U.S.A.). The sequences of
ODN for rat TGF- 1 mRNA (755 to 800 of the rat TGF- 1
mRNA sequence, GenBank, accession X52498) are as fol-
lows:
Antisense,
5′ -TGTGTGTGATGTCTTTGGTTTTGTCATAGAT-
TTCGTTGTTGCGGTC-3′ ; 
Sense,
5′ -GACCGCAACAACGCAATCTATGACAAAACCA-
AAGACATCACACACA-3′ .
To form a closed structure, both antisense ODNs and sense
ODNs were modified. The 5′end of ODNs has 8 bases of
sequence of 5′ -GATCACGT-3′ , while the 3′ end of ODNs
has 4 bases of sequence of 5′ -ACGT-3′ . The modified 58-
nucleotides (nt) ODNs were custom-synthesized by Bionics
(Seoul, Korea). The linear 58-nt ODNs were joined by the
complementary 4 base sequences (5′ -GATC-3′ ) at the 5′ ends.
Briefly, 60  g of linear antisense TGF- 1 ODNs were incu-
bated in a final volume of 100  L containing 1×ligase buffer
and 3,500 U T4 DNA ligase (Takara, Otsu, Japan) at 16℃
for 24 hr. The formation of circular ODNs (116-nt) was con-
firmed by electrophoresis on a 6% denaturing polyacrylamide
gel containing 7 M urea.
Stability of circular antisense TGF- 1 ODNs
Circular antisense TGF- 1 ODNs and linear antisense
ODNs were incubated at 37℃for 24 hr with rat serum which
was not inactivated by heat to preserve nuclease activity. The
serum was added to ODNs in a 50% volume of reaction mix-
ture. ODNs were then extracted with phenol/chloroform (1:1,
v/v) and examined by electrophoresis on a 6% denaturing
polyacrylamide gel containing 7 M urea.
Cell culture
Rat mesangial cells (RMCs) were obtained from a culture
of glomeruli isolated from male Sprague-Dawley (SD) rats
weighing 100 to 150 g using differential sieving methods as
previously described (29). Isolated glomeruli were cultured in
RPMI 1640 (Gibco BRL, Gaithersburg, MD, U.S.A.) com-
plete medium containing 100 U/mL penicillin, 100  g/mL
streptomycin, 0.25  g/mL amphotericin B, 10 mg/L insulin,
6.7  g/L sodium selenite, 5.5 mg/L transferrin, and 20%
heat-inactivated fetal calf serum (FCS; HyClone, Logan, UT,
U.S.A.) at 37℃ in a humidified 5% CO2 atmosphere. The
identity of mesangial cells was confirmed by phase contrast
microscopy according to the morphologic criteria (30). RMCs
between the 10th and 15th passage were used for cell studies.
In vitro transfection of circular antisense TGF- 1 ODNs
and antisense study
RMCs were seeded at 2×104 cells/well in 8-well cham-
ber slides (Nunc, Inc., Naperville, IL, U.S.A.) and cultured in
RPMI 1640 complete medium for 24 hr. RMCs were serum-
starved for 48 hr in RPMI 1640 containing 0.5% FCS and
transfected with fluorescein-labeled-circular antisense TGF- 1
ODNs. Circular antisense TGF- 1 ODNs were labeled using
Label IT
® Fluorescein Nucleic Acid Labeling Kit (Panvera
Corp., Madison, WI, U.S.A.). Commercially available cationic
liposomes (LipofectAMINE PLUS
TM Reagent; Gibco BRL,
Gaithersburg, MD, U.S.A.) were used to facilitate the trans-
fection of ODNs into RMCs. Briefly, 0.5  g of ODNs in
DMEM (Gibco BRL, Gaithersburg, MD, U.S.A.) were mixed
with the Plus reagent and incubated at room temperature
for 15 min. The ODNs-Plus reagent were mixed with 2  g
of LipofectAMINE reagent and subsequently incubated at376 H.S. Jeong, K.K. Park, S.P. Kim, et al.
room temperature for 15 min. The cells were washed with
serum-free DMEM and then 0.03 mL/well of serum-free
DMEM was added to the cells. The ODNs-liposome com-
plexes were added drop by drop to each well and incubated
at 37℃ for 5 hr. Cells were then replaced with RPMI 1640
containing 17% FCS and incubated further at 37℃ for 24
hr. Finally, the RMCs were washed three times with phos-
phate-buffered saline (PBS) and fixed in methanol at 4℃for
10 min. The cells were mounted and observed through a
fluorescence microscope. The effect of antisense ODNs on
TGF- 1 mRNA expression in RMCs was investigated. Cells
were cultured at 2×105 cells/well in 6-well cell culture plates
(Nunc, Inc., Naperville, IL, U.S.A.) and circular antisense
(0.5  g or 1  g), linear antisense (0.5  g or 1  g), and cir-
cular sense (1  g) TGF- 1 ODNs were introduced selective-
ly into the cells as described above. 
Preparation of HVJ-liposome
The hemagglutinating virus of Japan (HVJ)-liposomes
were prepared as described previously (31) with minor modi-
fications. HVJ was grown in chorioallantoic fluid of 10-day-
old embryonated chicken eggs at 35.5℃. HVJ was collect-
ed by centrifugation at 3,000 rpm for 10 min and suspend-
ed with balanced salt solution (BSS; 140 mM NaCl, 5.4 mM
KCl, 10 mM Tris-HCl, pH 7.5). HVJ was purified by anoth-
er centrifugation at 12,000 rpm for 1 hr, resuspended with
BSS, and stored at 4℃ until it was used. Egg yolk phos-
phatidyl choline (ePC; Sigma, U.S.A.), dioleoyl phosphatidyl
ethanolamine (DOPE; Avanti Polar Lipid, Birmingham, AL,
U.S.A.), egg yolk sphingomyelin (eSph; Sigma, U.S.A.), bovine
brain phosphatidyl serine (bPS; Sigma, U.S.A.), and choles-
terol (Chol; Sigma, U.S.A.) were each dissolved in chloroform,
mixed in a weight ratio of 1.6:3:1.5:1.3:1.5, and then dried
with a rotary evaporator. The dried lipid mixture was hydrat-
ed in 200  L of BSS containing 10  g of the ODNs, mixed
with vigorous agitation, and filtered to form liposomes. The
liposomes were mixed with HVJ that had been inactivated
by ultraviolet irradiation. The mixture was incubated at 4℃
for 10 min and then at 37℃ for 60 min with gentle agita-
tion. Free HVJ was removed from the HVJ-liposome mixture
by sucrose density gradient centrifugation. The HVJ-lipo-
some suspensions were maintained at 4℃until it was used.
In vivo transfection of circular antisense TGF- 1 ODNs
To estimate the delivery efficiency of the circular antisense
TGF- 1 ODNs by intravenous administration, fluorescein-
labeled-circular antisense TGF- 1 ODNs were injected into
the tail vein of normal 6-week-old male SD rats by the HVJ-
liposome mediated gene transfer method. Kidney, liver, lungs,
and spleen were removed 24 hr after injection. Four- m thick
cryostat sections of unfixed snap-frozen specimens were ob-
served through a confocal laser scanning microscope (TCS/
SPII, Leica, Wetzlar, Germany).
STZ-induced diabetic rats
Diabetes was induced in 21 male SD rats (180-210 g) by
a single intraperitoneal injection of 70 mg/kg STZ (Sigma,
U.S.A.) dissolved in 10 mM sodium citrate buffer (pH 4).
Blood glucose was measured using reagent strips (MediS-
ense, Bedford, MA, U.S.A.) 48 hr after STZ administration.
Animals with blood glucose >15 mM were included in this
study. All of the animals had unlimited access to standard
rat food and water. STZ-induced diabetic rats were separated
into two groups. One group (ODNs-treated diabetic rats)
was treated with circular antisense TGF- 1 ODNs and the
other group (untreated diabetic rats) was not. Once hyper-
glycemia was detected, HVJ-liposome mediated circular anti-
sense TGF- 1 ODNs were injected into the tail vein of the
diabetic rat the following day. Each group was sacrificed on
day 1, 5, and 13 after injection of ODNs. Normal rats were
sacrificed on day 13. Rats were anesthetized with ethyl ether
and the kidneys were removed, immediately frozen in liquid
nitrogen, and stored at -70℃ for subsequent RNA extraction.
Portions of tissues were fixed in neutral buffered formalin for
immunohistochemical staining. At the end of each experi-
mental periods, individually collected urine was centrifuged
at 3,000 rpm at 4℃ for 10 min. The supernatant was col-
lected and stored at -70℃until it was used.
RNA Isolation and RT-PCR
Total RNA was extracted from cultured RMCs and frozen
kidneys with RNAzol B (TEL-TEST, Friendswood, TX,
U.S.A.) according to the manufacturer’s instructions. The
purity and quantity of the RNA preparation were determined
by measuring the optical densities at 260 and 280 nm. Total
RNA was reverse transcribed with oligo-d(T)15 primers and
M-MLV reverse transcriptase (Promega, Madison, WI, U.S.A.).
Aliquots of cDNA were amplified by PCR using primer sets
specific to rat TGF- 1 and a constitutively expressed house-
keeping gene, glyceraldehyde-3-phosphate-dehydrogenase
(GAPDH) as the control. The primers used for PCR are as
follows:
Rat TGF- 1 upstream CCTGCTGCTTTCTCCC-
TCAACC,
downstream CTGGCACTGCTTCCCG-
AATGTC; 
Rat GAPDH upstream GTGGACATTGTTGCCA-
TCAACG, 
downstream GAGGGAGTTGTCATA-
TTTCTCG.
The reaction was run for 25 cycles with a cycling parameter
of 30 sec at 95℃, 60 sec at 60℃, and 120 sec at 72℃. PCR
products were visualized on a 2% agarose gel. The amounts
of TGF- 1 mRNA were measured by densitometer and ex-Effect of Antisense TGF- 1 Oligodeoxynucleotides in Diabetic Kidney 377
pressed relative to the densities of GAPDH.
Immunohistochemical staining of TGF- 1
Paraffin-embedded sections obtained from the kidneys were
deparaffinized with xylene and graded ethanol solutions and
incubated in 3% H2O2 in methanol at room temperature for
20 min to block endogenous peroxidase activity. They were
then washed with PBS for 10 min, incubated at 37℃ for 30
min in 0.1% trypsin, and washed with PBS for 5 min three
times. Incubation with the first antibody (Rabbit anti-porcine
TGF- 1 polyclonal antibody; Cell Science, Norwood, MA,
U.S.A.) was performed at 37℃ for 1 hr. After three serial
washes with PBS, the sections were processed by an indirect
immunoperoxidase technique using a commercial kit (LSAB
kit; DAKO, Carpinteria, CA, U.S.A.), counterstained with
Mayer’s hematoxylin, and examined under light microscope.
TGF- 1 ELISA
Total TGF- 1 in rat urine was determined using a sand-
wich ELISA kit (TGF- 1 Emax ImmunoAssay System; Pro-
mega, Madison, WI, U.S.A.), following the instructions pro-
vided by the manufacturer (32). Acid activation of urine sam-
ples was required to convert latent TGF- 1 into active form
and record detectable levels of total TGF- 1. Samples were
activated with 1N HCl at room temperature for 30 min, fol-
lowed by neutralization with 1N NaOH. Samples were plat-
ed on microtiter plates coated with anti-TGF- 1 monoclon-
al antibody and incubated at room temperature for 3 hr with
shaking. After vigorous washing, wells were incubated over-
night with polyclonal anti-TGF- 1 at 4℃and washed. They
were then incubated with antibody conjugated with horse-
radish peroxidase at room temperature for 3 hr with shak-
ing. Following additional washes, color was developed by
adding peroxidase substrate in 3,3′ ,S,S′ -tetramethyl benzi-
dine solution. A standard curve was constructed using serial
dilutions of human TGF- 1. TGF- 1 levels in the samples
were determined from the standard curve.
Statistical analysis
The data are presented as mean±standard error (SE). The
statistical difference between means was determined using
the Student’s t-test; p<0.05 was considered significant.
RESULTS
Synthesis of circular antisense TGF- 1 ODNs
Circular antisense TGF- 1 ODNs (116-nt) synthesized
by T4 DNA ligase from linear ODNs (58-nt) and analyzed
by denaturing polyacrylamide gel electrophoresis had slow-
er mobility compared with linear ODNs (Fig. 1A).
Stability of circular antisense TGF- 1 ODNs
This test was performed to prove the stability of ODNs
against nucleases in serum. Linear antisense TGF- 1 ODNs
were completely digested after incubation for 24 hr in rat
serum. However, circular antisense TGF- 1 ODNs remained
Fig. 1. Photograph of stained 6% denaturing polyacrylamide gel showing relative mobilities of linear and circular antisense TGF- 1 oligo-
deoxynucleotides (ODNs). (A) Synthesis of circular antisense TGF- 1 ODNs from linear ODNs: lane 1, 58-nt linear antisense TGF- 1 ODNs;
lane 2, 116-nt circular antisense TGF- 1 ODNs. (B) Stability of circular and linear antisense TGF- 1 ODNs after the treatment with rat
serum: lane 1, untreated circular antisense TGF- 1 ODNs; lane 2, circular antisense TGF- 1 ODNs treated with 50% (v/v) rat serum for
24 hr; lane 3, untreated linear antisense TGF- 1 ODNs; lane 4, linear antisense TGF- 1 ODNs treated with 50% (v/v) rat serum for 24 hr.
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considerably intact after incubation for 24 hr in rat serum;
thus exhibiting markedly improved stability compared with
linear antisense ODNs (Fig. 1B).
In vitro uptake and localization of circular antisense
TGF- 1 ODNs
To examine the transfection efficiency and localization of
circular antisense TGF- 1 ODNs, fluorescein-labeled-cir-
cular antisense TGF- 1 ODNs were transfected to RMCs.
The cells were then evaluated by fluorescence microscopy.
Most of the RMCs exhibited strong fluorescence in the cyto-
plasm and nucleus (Fig. 2).
Comparison of the effects of circular antisense ODNs and
linear antisense ODNs on TGF- 1 mRNA expression of
RMCs
To examine the effect of antisense ODNs, circular antisense
ODNs (0.5  g or 1  g), linear antisense ODNs (0.5  g or 1
g), and circular sense TGF- 1 ODNs (1  g) were introduced
selectively into the RMCs. Total RNA was isolated from the
transfected cells and RT-PCR was performed. Compared with
the transfection of circular sense TGF- 1 ODNs (1  g) and
liposome alone, the transfection of circular antisense TGF- 1
ODNs reduced TGF- 1 mRNA levels. Furthermore, the
effect of circular antisense ODNs on the ablation of the TGF-
1 mRNA content was stronger than that of the linear anti-
sense ODNs in the same amount of ODNs. These results
indicated that circular antisense TGF- 1 ODNs were more
effective than linear antisense ODNs in reducing TGF- 1
mRNA expression (Fig. 3).
In vivo uptake and localization of circular antisense
TGF- 1 ODNs
To evaluate the efficiency of circular antisense TGF- 1
ODNs via intravenous administration, fluorescein-labeled-cir-
cular antisense TGF- 1 ODNs were introduced into the
tail vein of normal SD rats using the HVJ-liposome transfer
method. The kidney, liver, lungs, and spleen were removed 24
hr after the tail vein injection of ODNs and observed through
a confocal laser scanning microscope. Most of the tubular
epithelial cells exhibited strong fluorescence in the cytoplasms
and nuclei (Fig. 4A). In addition, results confirmed that
Values are expressed as mean±SE. STZ: streptozotocin.
*: p<0.05 (normal vs. diabetes).
No. Rats
Body weight
(g)
Blood glucose
(mM)
1 day after ODNs injection
Diabetes 3 192±8.82 24.18±4.60
ODNs-treated diabetes 3 200±11.55 26.57±0.51
5 day after ODNs injection
Diabetes 5 217±4.64 21.57±2.75
ODNs-treated diabetes 3 213±6.67 25.54±3.90
13 day after ODNs injection
Normal 3 325±2.89 5.52±0.35
Diabetes 4 210±5.40* 29.99±1.94*
ODNs-treated diabetes 3 210±7.64 32.53±0.80
Table 1. Values for body weight and blood glucose in STZ-in-
duced diabetic rats
Fig. 2. Fluorescence microscopy of rat mesangial cells transfected
with circular antisense TGF- 1 oligodeoxynucleotides (ODNs) in
cationic liposomes. Fluorescein-labeled-circular antisense TGF-
1 ODNs were observed in both the nuclei and the cytoplasm
(×400).
Fig. 3. Effect of circular antisense oligodeoxynucleotides (ODNs)
on TGF- 1 mRNA expression in rat mesangial cells (RMCs). RMCs
were serum-starved for 48 hr and subsequently transfected with
circular antisense ODNs (1  g)+cationic liposome (4  g) (lane
1), circular antisense ODNs (0.5  g)+cationic liposome (4  g)
(lane 2), linear antisense ODNs (1  g)+cationic liposome (4  g)
(lane 3), linear antisense ODNs (0.5  g)+cationic liposome (4  g)
(lane 4), circular sense ODNs (1  g)+cationic liposome (4  g)
(lane 5), and cationic liposome (4  g) alone (lane 6), and then
exposed to RPMI 1640 containing 17% FCS. Total RNA was iso-
lated from the RMCs and subjected to RT-PCR (TGF- 1: 598 bp,
GAPDH: 351 bp).
123456
TGF- 1
GAPDHEffect of Antisense TGF- 1 Oligodeoxynucleotides in Diabetic Kidney 379
ODNs were delivered mostly into liver, lungs, and spleen (Fig.
4B-D).
Blood glucose in STZ-induced diabetic rats
Table 1 shows the parameters measured during the induc-
tion of diabetes. Both circular antisense TGF- 1 ODNs-
treated diabetic rats and untreated diabetic rats had slightly
higher blood glucose level on day 13 after ODNs injection
compared to days 1 and 5. Treatment with circular antisense
TGF- 1 ODNs had little effect on the blood glucose level
of diabetic rats, however.
Effects of circular antisense ODNs on TGF- 1 mRNA and
protein expression in STZ-induced diabetic rats
The effect of circular antisense ODNs on TGF- 1 mRNA
and protein expression in diabetic kidneys was determined by
RT-PCR and immunohistochemical study. Circular antisense
TGF- 1 ODNs-treated and untreated diabetic rats were stud-
ied on days 1, 5, and 13 after the introduction of ODNs. On
day 13 after ODNs injection, TGF- 1 mRNA levels were
decreased significantly in circular antisense TGF-  1 ODNs-
treated diabetic rats compared with untreated diabetic rats
(0.82±0.05 vs. 1.32±0.01; p<0.05) (Fig. 5). Furthermore,
circular antisense TGF- 1 ODNs treatment markedly inhib-
Fig. 4. Confocal microscopy of rat organs transfected with fluorescein-labeled-circular antisense TGF- 1 ODNs in HVJ-liposome by intra-
venous systemic administration method (A: kidney, B: liver, C: lung, D: spleen, ×200).
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ited TGF- 1 protein expression in diabetic kidneys (Fig. 6).
On days 1 and 5 after ODNs injection, TGF- 1 was strongly
expressed in the glomerular endothelial cells and tubular
epithelial cells of the untreated diabetic kidneys (Fig. 6A, C),
while circular antisense TGF- 1 ODNs-treated diabetic
kidneys (Fig. 6B, D) showed mild TGF- 1 protein expres-
sion in the tubular epithelial cells. On day 13 after ODNs
injection, TGF- 1 was markedly expressed in the peritubu-
lar capillaries, glomerular endothelial cells, and tubular epithe-
lial cells of the untreated diabetic kidneys compared with
the circular antisense TGF- 1 ODNs-treated diabetic kid-
neys (Fig. 6E-G).
Effect of circular antisense ODNs on urinary TGF- 1
excretion rate of diabetic rats
Urinary excretion rate of total TGF- 1 (latent plus active
fractions) markedly increased in both untreated and circular
antisense TGF- 1 ODNs-treated diabetic rats. On days 1 and
5 after ODNs injection, the urinary TGF- 1 excretion rates
of circular antisense TGF- 1 ODNs-treated diabetic rats were
not significantly different from that of the untreated diabetic
rats. In contrast, on day 13 after ODNs injection, the urinary
TGF- 1 excretion rate of circular antisense TGF- 1 ODNs-
treated diabetic rats showed approximately 25% reduction
compared with that of the untreated diabetic rats (Fig. 7).
DISCUSSION
Much attention has been focused on exploring mechanisms
related to the development of diabetic nephropathy. Among
the mechanisms, TGF- 1 has been implicated as an etiolog-
ic cause in its progression. TGF- 1 is a key mediator of the
hyperglycemia-induced panoramic effects on cell growth and
extracellular matrix accumulation (7, 9-11, 13, 14). In addi-
tion, this cytokine has powerful fibrogenic potential because
of its capability for simultaneous actions such as stimulation
of matrix synthesis, inhibition of matrix degradation, and
modulation of matrix receptor expression to facilitate cell mat-
rix interactions (16). Thus, TGF- 1 has been considered as
a therapeutic target in fibrotic disease such as diabetic nephro-
pathy and other chronic kidney diseases, and anti-TGF- 1
therapies have also been performed (17-20).
B A
Fig. 5. RT-PCR analysis of the effect of circular antisense oligodeo-
xynucleotides (ODNs) on TGF- 1 mRNA expression in diabetic
kidneys on days 1, 5, and 13 after injection of ODNs into diabetic
rats. Lane 1, normal kidney; lane 2, on day 1, untreated diabetic
kidney; lane 3, on day 1, ODNs-treated diabetic kidney; lane 4,
on day 5, untreated diabetic kidney; lane 5, on day 5, ODNs-
treated diabetic kidney; lane 6, on day 13, untreated diabetic kid-
ney; lane 7, on day 13, ODNs-treated diabetic kidney (TGF- 1:
598 bp, GAPDH: 351 bp).
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Fig. 6. Immunohistochemical staining of TGF- 1. On day 1 after injection of circular antisense TGF- 1 oligodeoxynucleotides (ODNs) into
diabetic rats, ODNs-treated diabetic kidney (B), on day 5, ODNs-treated diabetic kidney (D), on day 13, ODNs-treated diabetic kidney
(G), and their respective controls (A, C, E, F: untreated diabetic kidney) (×200). (continued next)Effect of Antisense TGF- 1 Oligodeoxynucleotides in Diabetic Kidney 381
More recently, gene therapy using antisense ODNs as one of
the anti-TGF- 1 therapies has been investigated and applied
to renal disease (21, 31, 33). In the period of early gene thera-
py, a major problem was the rapid degradation of phospho-
diester antisense ODNs by nuclease both in vitro and in vivo.
To improve the biological instability of antisense ODNs,
chemical modifications of the phosphate backbone or bases
were attempted and ODNs such as phosphorothioate, methyl-
phosphate, and phosphoramidate analogues have been devel-
oped (22). In particular, phosphorothioate (PS)-ODNs have
been studied mainly in animal models of kidney disease where
one of the non-bridging oxygens in the phosphodiester back-
bone is replaced with a sulfur atom. However, PS-ODNs were
found to have non-sequence-specific effects because of their
polyanionic nature (25, 26). 
Circular antisense TGF- 1 ODNs used in the present work
were synthesized from linear antisense ODNs, retaining the
integrity of the phosphodiester backbone of the ODNs for
its stability to nuclease attack. Theoretically, these ODNs
could resist exonuclease attack with excellent binding affini-
ty, sequence specificity, and ability to activate RNase H since
they possess no 5′ or 3′ end. In this study, it was shown that
Fig. 6. (Continued from the previous page) Immunohistochemical staining of TGF- 1. On day 1 after injection of circular antisense TGF- 1
oligodeoxynucleotides (ODNs) into diabetic rats, ODNs-treated diabetic kidney (B), on day 5, ODNs-treated diabetic kidney (D), on day
13, ODNs-treated diabetic kidney (G), and their respective controls (A, C, E, F: untreated diabetic kidney) (×200).
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circular antisense ODNs in rat serum were less digested than
linear ODNs. The ablation of the TGF- 1 mRNA was more
marked in the circular antisense ODNs than in the linear
antisense ODNs treated RMCs. These results indicate that
circular antisense TGF- 1 ODNs are superior to linear anti-
sense ODNs. Furthermore, circular antisense TGF- 1 ODNs
markedly suppressed the levels of TGF- 1 mRNA and protein
in diabetic kidneys. Its specific activity in blocking TGF- 1
expression was demonstrated by the observed absence of dif-
ference in the level of GAPDH mRNA. An enhanced stabil-
ity of the circular antisense TGF- 1 ODNs could enable less
frequent dosing because of its longer duration of action, there-
by reducing potential unwanted side-effects from fewer degra-
dation metabolites. 
Various routes for the efficient transfer of ODNs into the
kidney have been tried in experimental models. Akagi et al.
(31) reported transfection of ODNs via renal artery in the
anti-Thy glomerulonephritis model. Isaka et al. (33) intro-
duced retrograde transfection of ODNs via the ureter in the
unilateral ureter obstruction model. Han et al. (21) reported
systemic infusion of ODNs through implanted osmotic pump
in diabetic mice. All these works should be performed with
minor-surgery for administration and would be quite trou-
blesome in case of repetitive administration. Morishita et al.
(34) attempted systemic administration via the tail vein for
insulin vector transfer, resulting in the expression of insulin
vector in the liver and spleen. Others reported that circulat-
ing ODNs could reach and accumulate in the kidney (35, 36).
With those reports taken into consideration, the present study
used intravenous administration to transfer ODNs to the
kidney. After the intravenous administration, circular anti-
sense TGF- 1 ODNs appeared in the liver, lungs, spleen,
and kidney. In the kidneys, they appeared mainly in the tubu-
lar epithelial cells. In addition, they inhibited effectively the
expression of TGF- 1 mRNA and protein in diabetic kidneys.
These results are consistent with the notion that systemic
administration of antisense TGF- 1 ODNs is effective in
reducing TGF- 1 expression (21). The study also employed
HVJ-liposome method for the effective delivery of ODNs
into kidney cells because of the several advantages of this
delivery system, such as rapid translocation to the nucleus
and stability of the transfected ODNs in the nucleus (37).
In the long-term diabetic state, TGF- 1 may perpetuate
the disease process by inducing persistent hyperglycemia. In
this regard, it seems necessary to perform further studies on
the long-term blockade of progression of diabetic nephropa-
thy and renal failure through treatment with circular anti-
sense TGF- 1 ODNs.
In conclusion, the effect of circular antisense TGF- 1 ODNs
designed for stability against nucleases was superior to that
of the linear antisense ODNs on TGF- 1 mRNA expression
in RMCs. Circular antisense TGF- 1 ODNs suppressed effi-
ciently the expression of TGF- 1 in the mRNA and protein
levels by intravenous administration combined with HVJ-
liposome in STZ-induced diabetic rats. These findings sug-
gest that circular antisense TGF- 1 ODNs may be a useful
tool for developing new therapeutic application for progres-
sive diabetic nephropathy.
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